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LuteolysisThe ovary is a dynamic organ that undergoes cyclic structural and functional changes. Structurally, the inter-
nal architecture of the ovary constantly changes as follicles grow, rupture and transform into corpora lutea in
a cyclical manner. Functionally, a variety of regulatory ovarian hormones are sequentially produced, and eggs
are periodically released. As a highly vascularized organ, the ovarian structures and functions change in re-
sponse to external stimuli that include but are not limited to pituitary gonadotropins. Following stimulation,
the ovary synthesizes and releases autocrine and paracrine signals that play unique roles in regulating its
function. Recent studies have identiﬁed endothelins as local regulators in the ovary that modulate multiple
cyclic events, such as follicle growth, steroidogenesis, oocyte maturation, ovulation, corpus luteum formation
and luteolysis. Interestingly, in all mammalian species examined to date, a common observation has been
made: the ovary produces two pharmacologically similar endothelins (ET-1 and ET-2) but expresses two
functionally different endothelin receptors (ETA and ETB) that often give rise to opposite physiological out-
comes following activation by an endothelin. In this review, the physiological signiﬁcance of the presence
of the two ligand-two receptor endothelin system in the ovary will be discussed.
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The ovary contains follicles that increase in size, release eggs, trans-
form into corpora lutea and ﬁnally regress. These cyclic events begin
with the onset of puberty and diminish when the follicular pool be-
comes depleted. The two pituitary hormones, follicle stimulating hor-
mone (FSH) and luteinizing hormone (LH), play key roles in
maintaining the continuity of these cycles by triggering biochemical
and structural changes within the ovary. Changes such as these arerative Biosciences, College of
hampaign, 3806 VMBSB, MC-
USA. Tel.: +1 217 333 9362
 CC BY-NC-ND license.initiated by the pituitary hormones and are mostly driven by signaling
molecules that are synthesized locally in the ovary (Richards and
Pangas, 2010). Among the ovarian signalingmolecules are endothelins.
Our understanding of the role of endothelins in regulating ovarian
function has increased markedly in recent years (Bridges et al., 2011;
Meidan and Levy, 2007). Lately, discoveries in the ovary using both
pharmacological and genetic approaches have generated excitement
in the ﬁeld of endothelin research not only because of discoveries spe-
ciﬁc to this reproductive organ but also because of the potential impact
on other endothelin ﬁelds of study. Because the ovary is a highly vascu-
larized organ, dynamic changes in blood ﬂow occur under the inﬂuence
of a variety of locally produced factors, such as prostaglandins and
endothelins. Different members of these groups of hormones are in-
volved in ovulation and the corpus luteum functions (Bridges et al.,
2011; Duffy et al., 2005; Kurusu et al., 2009). The dynamic nature of
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ing the mechanism of the endothelin system.
Endothelins regulate many ovarian functions including
folliculogenesis, steroidogenesis, oocyte maturation, ovulation, luteal
formation and regression (Apa et al., 1998; Klipper et al., 2010; Ko et
al., 2006; Li et al., 2011; Mancina et al., 1997; Palanisamy et al., 2006;
Usuki et al., 1993). Therefore, it is not surprising that all the components
of the endothelin system, such as endothelins, endothelin-converting
enzymes and endothelin receptors, are expressed in all of the mamma-
lian ovaries examined to date. The ET-1 and ET-2 endothelin isoforms,
but not ET-3, and at least two forms of endothelin-converting enzymes
(ECE1 and ECE2) are expressed in this female gonad. Similar to other or-
gans, two G protein-coupled receptors, endothelin receptor type A
(ETA) and type B (ETB), which have different molecular and pharmaco-
logical characteristics, are present in the ovary and are believed to be re-
sponsible for the actions of these ligands (Bridges et al., 2011; Choi et al.,
2011; Ko et al., 2006). In general, the two dissimilar endothelin recep-
tors are constitutively expressed but are spatially conﬁned to speciﬁc
cell types in the ovary; a number of cells express both receptors, where-
as other cells express one form or the other. For example, in the human
ovarian follicle, the smoothmuscle cells of the theca externa express the
ETA receptor, whereas ETB receptor expression is conﬁned to theca
interna that surrounds the entire follicle (Choi et al., 2011). The theca
interna is a highly vascularized cell layer that contains steroidogenic
cells and separates the theca externa from the core of the follicle. The
endothelin receptor expression is also apparent in the granulosa cells
of the follicle (Gentili et al., 2001) as well as the corpus luteum. In the
corpus luteum, the ETA receptor is expressed in the small and large lu-
teal cells (Mamluk et al., 1999), and both receptor subtypes are local-
ized in the endothelial cells of this highly vascularized tissue (Karam
et al., 1999; Mamluk et al., 1999).
The synthesis of the two functionally similar endothelin isoforms, ET-
1 and ET-2, is temporally controlled regardless of the cell type. Although
the level ﬂuctuates, ET-1 expression in granulosa cells is somewhat con-
stitutive. In contrast, ET-2 is transiently and abundantly expressed only
in the granulosa cells of ovulating follicles (Ko et al., 2006; Palanisamy
et al., 2006). Endothelin-converting enzymes are expressed throughout
the reproductive cycles with minimal changes in their expression levels.
Dramatic changes in endothelin receptor expression are not observed
during the course of follicular development; however, speciﬁcity is ob-
served of the sites of expression (Ko et al., 2006; Palanisamy et al.,
2006). Therefore, it is likely that the endothelin-mediated regulation of
ovarian events is manifest by both the temporal and the spatial control
of endothelin synthesis and the distribution of endothelin receptors.
ET-1 and ET-2 bind to the ETA receptor with equivalent afﬁnities and
induce prolonged vasoconstrictionwhen activated. The ETB receptor also
binds both ET-1 and ET-2with equal afﬁnity; however, the binding of ei-
ther endothelin to this receptor elicits physiological responses that are
largely opposite to those elicited by ETA receptor binding in that endo-
thelin binding of the ETB receptor in endothelial cells causes vasodilation
by inducing nitric oxide (NO) signaling pathways. Because of their slow
turnover rate, ETB receptors can act as scavengers, removing bound
endothelins from the external milieu (Bremnes et al., 2000; Inoue et al.,
1989; Yanagisawa et al., 1988). The physiological signiﬁcance of co-
expressing these two receptors in the ovary is not known, and the bio-
logical mechanism underlying how the receptors cooperate to induce a
physiological outcome is of great interest not only to understand ovarian
endothelin function but also for the general understanding of the activity
of endothelins in other organs and systems.
Most of the organs/tissues examined to date express both types of
endothelin receptors. Therefore, a physiological outcome of endo-
thelin activity in an organ or tissue should be a result of its binding
to both endothelin receptors. It is highly plausible that the activation
of one receptor may elicit more obvious or discernable physiological
responses than the other. However, while less prominent, the role
the other receptor plays may be ‘essential’ for the correct regulationof the physiological function. This hypothesis suggests that when
this proposed ‘essential’ regulation is lost, an extreme physiological
outcome may follow, leading to the hyper-stimulation or hypo-
stimulation of the endothelin-regulated physiological event; for ex-
ample, the ovulatory process may continue instead of being terminat-
ed by this transient event, or a corpus luteum may persist when it is
expected to demise. Currently, controversy surrounds a number of
studies of the ovarian endothelin system, whereas the results of
other studies are consistent (Hinckley and Milvae, 2001; Ko et al.,
2006; Palanisamy et al., 2006; Weems et al., 2009). The controversies
include whether the ETA receptor or the ETB receptor is responsible
for regulating a particular ovarian function. Because both receptors
are constitutively expressed in the ovary, each of the endothelin-
regulated ovarian functions may require the activation of both recep-
tors, or a single receptor may play a dominant role. In this review, the
physiological signiﬁcance the two endothelin receptors expressed in
the ovary will be discussed with respect to the regulation of ovulation
and the corpus luteum formation.
The components of the endothelin system and the major biosyn-
thetic processes involved have been described by others (Kawanabe
and Nauli, 2011; Khimji and Rockey, 2010; Kido et al., 1998; Masaki
et al., 1999), and the ovarian endothelin system and its known func-
tions have been summarized previously (Bridges et al., 2011; Meidan
and Levy, 2007); therefore, these aspects of the endothelin system
will receive only minimal attention in this review.
Ovulatory regulation
The main function of an ovary is to produce eggs, which is a criti-
cally important biological event for the propagation of life. Ovulation,
ending with the rupture of the follicular wall and the expulsion of the
oocyte, is a central event and the hallmark of ovarian function. The
mechanism governing follicle rupture has challenged researchers for
decades and is still revealing its secrets. In the past, increased intra-
follicular pressure was considered to be the driving force in follicle
rupture (Espey and Lipner, 1963; Schroeder and Talbot, 1982). How-
ever, this concept has been challenged because the presumed pres-
sure increase at the time of follicle rupture has never been
documented (Espey and Lipner, 1963; Rondell, 1964). Instead, more
attention has focused on the view that ovulation results from the pro-
teolytic degradation of the follicular wall, which is supported by the
functional presence of matrix metalloproteinases/plasminogen acti-
vators and inﬂammatory leukocytes in the ovary (Brannstrom and
Enskog, 2002; Curry and Osteen, 2003; Oakley et al., 2010, 2011;
Richards et al., 2002).
Electron microscopy and immunohistochemical examination re-
vealed that the follicles are surrounded by layers of smooth muscle
cells. In effect, follicles are interwoven with their neighboring coun-
terparts (Choi et al., 2011; Ko et al., 2006; Schroeder and Talbot,
1982). This structural connectivity makes the entire ovarian smooth
muscle network resemble a “sponge”. In fact, isometric examination
veriﬁed that the ovary as a whole exhibits a dynamic contractile re-
sponse following its exposure to stimulants (Martin and Talbot,
1981; Schroeder and Talbot, 1982; Talbot and Chacon, 1982). These
ﬁndings led to the hypothesis that follicle rupture may be a result of
active follicular constriction, whereas the above-mentioned increased
follicular tension and the protease-driven weakening of the follicle
wall may help to rupture this structure when the follicle wall
constricts.
The search for an intra-ovarian factor that induces follicular constric-
tion resulted in an extraordinary discovery: ET-2 is synthesized by the
ovulating follicles during an extremely narrow temporal window
(~2 h) prior to follicle rupture (Ko et al., 2006; Ling et al., 2011;
Palanisamy et al., 2006). Subsequent functional investigations deter-
mined that ET-2 induces a rapid and sustained constriction in ovarian
strips. The constriction was shown to be induced via endothelin
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stripswith tezosentan, a dual endothelin receptor antagonist, abolished
the ET-2-induced constriction (Ko et al., 2006). When administered in
vivo, this dual endothelin receptor antagonist caused amarked decrease
or delay in ovulation, demonstrating the importance of the endothelin
receptor(s) in regulating ovulation. Notably, although a number of dis-
crepancies have been reported among different species and by different
laboratories, ET-1, the ETA receptor and the ETB receptor are expressed
constitutively during the periovulatory period, and dramatic changes
in the expression levels are not observed (Ko et al., 2006; Ling et al.,
2011; Palanisamy et al., 2006).
When exposed to either ET-1 or ET-2, the ovarian strips display
almost identical contractile responses. Why then does the ovary
express both ET-1 and ET-2? When considering this question, it is
worth noting that ET-1 is constitutively expressed at a relatively
low level that does not change dramatically during the entire pre-
and post-ovulatory period. In contrast, ET-2 is transiently and highly
expressed at the time of ovulation; otherwise, its expression is either
absent or is undetectable (Ko et al., 2006; Ling et al., 2011;
Palanisamy et al., 2006). Whereas there is a possibility that ET-1
and ET-2 may elicit different physiological outcomes (Ling et al.,
2011), this is not likely for the regulation of ovarian contractility be-
cause both isoforms induce a similar contractile physiological re-
sponse (Al-Alem et al., 2007; Bridges et al., 2010; Ko et al., 2006). It
will be interesting to examine if the constitutively produced ET-1 is
required for maintaining the basal contractile tone of the ovary, and
if the transiently and abundantly produced ET-2 instantly increases
the total ovarian endothelin content above the threshold level that
is required for triggering the ovary to constrict.
The ETA receptor and the ETB receptor are expressed in the ovary.
Isometric measurements using strips of rat ovaries in vitro showed
that endothelins (ET-1 or ET-2) trigger ovarian constriction via the
ETA receptor (Bridges et al., 2010). In this study, the ovaries con-
tracted in the presence of an ETB receptor antagonist (3 μM of
BQ788) but did not contract in the presence of an ETA receptor antag-
onist (3 μM of BQ123). Conversely, the endothelin-induced ovarian
constriction was relieved by the subsequent treatment with the ETA
receptor antagonist (10 μM of BQ123) but not the ETB receptor antag-
onist (10 μM of BQ788). This result appears to support the general
concept that endothelin induces vasoconstriction via the ETA recep-
tor, whereas vasodilation is induced by an ETB receptor-mediated
pathway. The experimental results clearly demonstrate that the ETA
receptor is responsible for the endothelin-induced constriction. How-
ever, it is presumptive to conclude from this experiment that the ac-
tivation of the ETB receptor leads to ovarian relaxation (similar to
vasodilation in vessels) because the relaxation induced by BQ123 in
the constricted ovary may be a result of the loss of ETA receptor activ-
ity rather than the ‘presumed’ relaxation-inducing activity of the ETB
receptor in the absence of ETA receptor signaling. Therefore, the as-
sessment of a dose-dependent contractile/relaxation response to
endothelins in the presence or absence of ETA receptor antagonism
is warranted. In addition, it is important to determine if the ovarian
ETB receptor passively antagonizes ETA receptor-mediated endothelin
activity by reducing the total ovarian endothelin content via the well-
established role of the ETB receptor in endothelin clearance (Bremnes
et al., 2000). A comparative measurement of the endothelin clearance
rates in the ovaries of rescued ETB receptor knockout animal models
(Nishida et al., 2002; Riechers et al., 2004) versus control animals,
followed by assessing the functional signiﬁcance of the ETA receptor
deﬁciency on the ovarian contractile response, will address further
the role of the ETB receptor in regulating ovarian contractility.
With emphasis on the ETB receptor expression in granulosa cells
and in the theca interna, an ETB receptor-mediated pathway leading
to follicle rupture has also been proposed (Palanisamy et al., 2006).
This hypothesis suggests that the ET-2 produced by granulosa cells
acts on either the granulosa cells or the endothelial cells of theblood vessels in the theca interna via the ETB receptor to induce nitric
oxide signaling, local vasodilation and an increase in follicular pres-
sure. In support of this hypothesis, Palanisamy et al. (2006) reported
that the treatment with an ETB receptor antagonist inhibited ovula-
tion in gonadotropin-primed mice. In the same experiments, an ETA
receptor antagonist did little to inhibit ovulation. Interestingly, Brid-
ges et al. were not able to block ovulation using these receptor-
speciﬁc antagonists (Bridges et al., 2010). These contrasting results
may be caused by differences in the pharmacokinetics of the antago-
nists (slight differences in the times of treatment were noted be-
tween the two studies) and/or subtle differences in the animal
models used. Therefore, further studies are warranted, including the
ovary-speciﬁc deletion of the ETA receptor using conditional ETA re-
ceptor knockout mice (Ruest et al., 2005) or rescued ETB receptor
knockout animal models (Nishida et al., 2002; Riechers et al., 2004).Regulation of the corpus luteum life span
The ovulatory surge of gonadotropins triggers extensive structural
andmolecular changes in the preovulatory follicle, leading not only to
ovulation but also to luteal formation (Robker et al., 2000). Luteal for-
mation is a complex process involving mechanisms similar to wound
healing and tumor formation, and robust angiogenesis is involved in
the process (Nakhuda et al., 2005). Because of the development of
an elaborate network of blood vessels in the corpus luteum, this
gland exhibits one of the highest blood ﬂows per unit mass of any tis-
sue in the body (Niswender et al., 2000; Stocco et al., 2007), which is
essential for supplying nutrients and hormones for proper function-
ing. The primary function of the corpus luteum is to produce proges-
terone, which is required for establishing and maintaining pregnancy.
Progesterone exerts its critical role by inducing a state of quiescence
in the myometrium, suppressing the maternal immune response to
the fetal antigens, reducing cyclic ovarian activity during pregnancy,
and it is responsible, at least in part, for mammary development
(Nardo and Sallam, 2006; Ouzounian et al., 2008). Because of this
unique role and its requirement for pregnancy, the formation and
maintenance of the corpus luteum are tightly regulated. As such, lute-
al defects in women are often the cause of early miscarriage (Nardo
and Sallam, 2006; Tavaniotou et al., 2001). In forming a corpus
luteum, a large number locally produced agents complement the ac-
tion of gonadotropins (Korzekwa et al., 2010; Schams and Berisha,
2004; Stocco et al., 2007). However, inadequate luteal formation or
function despite what appears to be a normal LH surge has been doc-
umented. Endothelins are an important component of the local fac-
tors that are intricately involved in regulating luteal function
(Meidan and Levy, 2007). Indeed, all members of the EDN system
are expressed in the corpora lutea of various mammalian species
(Choi et al., 2011; Flores, 2000; Hinckley and Milvae, 2001; Mamluk
et al., 1999; Zorrilla et al., 2010).
Endothelins exhibit a unique proﬁle in the corpus luteum (Klipper
et al., 2010; Ko et al., 2006). ET-2 mRNA expression is transiently in-
duced in luteal steroidogenic cells during the early luteal phase and
subsequently decreases to basal levels by the mid-luteal phase. In
contrast, ET-1 mRNA remains constant during this period. Hypoxia
is a strong inducer of ET-2 transcription in all species examined
(Kim et al., 2009; Klipper et al., 2010; Na et al., 2008). It is noteworthy
that hypoxia also stimulates VEGF expression and therefore luteal an-
giogenesis (Berisha et al., 2008; Tesone et al., 2005). Interestingly, ET-
2 induces VEGF in the granulosa cells (Klipper et al., 2010), suggesting
that elevated ET-2 in the newly formed corpus luteum, triggered by
hypoxia, may facilitate luteal formation by promoting angiogenesis.
Unfortunately, the endothelin receptor(s) responsible for these activ-
ities and their downstream signaling pathways have yet to be de-
scribed. It will be interesting to determine how the ETA and/or ETB
receptors are expressed in the different luteal cell types and how
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tion and function.
In the absence of an embryonic signal, the corpus luteum re-
gresses, which is necessary for the initiation of a new reproductive
cycle. Prostaglandin F2α (PGF2α) is the principal luteolytic hormone
(Niswender et al., 2000; Schams and Berisha, 2004). In a non-fertile
cycle, PGF2α is secreted from the uterus to induce luteal regression
(McCracken et al., 1972). Initially, luteal steroidogenic function is im-
paired, and progesterone production declines (Niswender et al.,
2000). This process is followed by the apoptosis of luteal cells and
the structural demise of the corpus luteum (Niswender, 2002;
Yadav et al., 2005). Based on these well-established ﬁndings, PGF2α
is routinely used to induce luteolysis and for synchronizing estrous
cycles in domestic species. Studies performed over the past two de-
cades have identiﬁed ovarian ET-1 as a mediator of the luteolytic cas-
cade in many species (Girsh and Dekel, 2002; Meidan and Levy, 2002;
Meidan et al., 1999; Weems et al., 2009; Wijayagunawardane et al.,
2001; Wright et al., 2001). However, consistent with the alternate hy-
potheses noted above, a number of ﬁndings suggest a contrasting role
for ET-1 in ovulation. It has been reported that the infusion of ET-1
prevents the decrease in luteal weight and the decline in progester-
one that occurs during luteal regression in ewes (Weems et al.,
2009), and the authors propose that ET-1 plays an anti-luteolytic
role. Interestingly, these authors also report that ET-1 increases the
secretion of anti-luteolytic PGE2 by pieces of caruncular endometri-
um (Weems et al., 2005). In contrast, and in support of a luteolytic
role for ET-1, a marked and rapid increase in luteal endothelin con-
centrations occurs soon after endogenous PGF2α secretion and after
the administration of a luteolytic dose of PGF2α (Girsh et al., 1996;
Hinckley andMilvae, 2001; Ohtani et al., 1998). Furthermore, ET-1 in-
hibits basal and gonadotropin-stimulated progesterone synthesis in a
dose-dependent manner in bovine (Girsh et al., 1996), ovine (Doerr
et al., 2008; Hinckley and Milvae, 2001), rodent (Girsh and Dekel,
2002) and human (Apa et al., 1998) luteal cells. The ETA receptor is
likely responsible for this ET-1 activity because co-treatment with
an ETA receptor-speciﬁc antagonist, but not an ETB receptor antago-
nist, abolishes the anti-steroidogenic activity of ET-1 (Girsh and
Dekel, 2002; Meidan and Levy, 2002).
Because ET-1 is involved in luteal regression, efforts have been
made to manipulate ovarian cyclicity using this peptide. Intra-luteal
ET-1 injections were shown to reduce progesterone secretion and fa-
cilitate the luteolytic process during the mid-luteal phase in cows
(Shirasuna et al., 2006). In addition, following injection of the ETA re-
ceptor antagonist LU 135252 into the corpora lutea of naturally cy-
cling animals, structural luteolysis and progesterone synthesis were
delayed signiﬁcantly (Watanabe et al., 2006). In a different study,
using Alzet mini-osmotic pumps implanted in the ewe's ovary, treat-
ment with the ETA receptor antagonist (BQ-610) alone or in combina-
tion with the ETB receptor antagonist (BQ-788) markedly reduced
luteal progesterone content. In contrast, treatment with BQ-788
alone had no effect on progesterone content (Doerr et al., 2008).
These in vivo studies support the previous in vivo and in vitro obser-
vations showing that ET-1, acting through the ETA receptor, is an en-
dogenous mediator of the luteolytic effect of PGF2α on luteal
progesterone secretion as well as on the structural demise of the CL;
however, the evidence supporting an anti-luteolytic role for ET-1
must also be considered. Although, the data presented indicate that
the ETB receptor does not play an obvious role in this process, the pos-
sibility remains that this receptor acts as a facilitator of endothelin
clearance. Therefore, it is likely that important new information will
be obtained regarding luteolysis and/or endothelin clearance in CL
by assessing the effect of the luteal cell-speciﬁc deletion of the ETA re-
ceptor using conditional ETA receptor knockout mice (Ruest et al.,
2005) and/or measuring the loss of function of ETB receptor using
rescued ETB receptor knockout animal models (Nishida et al., 2002;
Riechers et al., 2004).Summary and further considerations
The endothelin system has been recognized as a critical regulator
of ovarian function (Bridges et al., 2011; Meidan and Levy, 2007).
However, in stark contrast to the large amount of information that
points to the pivotal role endothelins play in regulating each ovarian
function, the mechanism underlying how endothelins regulate ovari-
an functions is not well understood. It is particularly important to un-
derstand the physiological roles of the ETB receptor. Currently, a role
for the ETB receptor in the ovary has not been deﬁned; the majority of
endothelin-regulated ovarian processes appear to be regulated by the
ETA receptor. The absence of ETB receptor-regulated ovarian functions
suggests that this receptor may not mediate an endothelin-driven
event but may act as a terminator of individual events by facilitating
the removal of endothelins (Fig. 1). The known role for the ETB recep-
tor as a facilitator of endothelin clearance ﬁts this scenario. As a clear-
ance facilitator, the ETB receptor might contribute to the maintenance
of endothelin homeostasis; the endothelins that are continuously
or transiently synthesized must be removed for an endothelin-
regulated event to be terminated. Although these presumptive roles
for the ETB receptor require experimental veriﬁcation, it would be in-
teresting to re-evaluate the existing experimental data to investigate
a possible role for the ETB receptor as a facilitator that terminates
endothelin-induced ovarian processes.
During the preovulatory period, ET-1 and ET-2 are expressed in
completely different manners; whereas ET-2 expression is induced
abundantly and transiently in the granulosa cell layer, ET-1 is mini-
mally and constitutively expressed (Fig. 1). It is not known if ET-1
and ET-2 exhibit the same biological activities for the induction of
ovulation. If they do have equivalent biological activities, the tran-
sient and abundant expression of ET-2 suggests that the ET-2 gene
is only stimulated when increased levels of ovarian endothelin are re-
quired. If this fascinating hypothesis is true, there is a possibility that
ET-2 expression may be induced in other organs where endothelins
play important regulatory roles. During the luteal period, however,
the speciﬁcity of the ET-1 and ET-2 activities in the corpus luteum
lies in their distinct temporal and cell-speciﬁc expression patterns.
ET-1 and ET-2 are induced in different cell types in the corpus luteum
(endothelial vs. luteal, respectively) and are controlled by different
factors (PGF2α vs. LH/hypoxia, respectively). Therefore, these two
very similar peptides appear to act at discrete luteal stages: ET-1 in
the luteal regression stage and ET-2 in the luteal formation stage
(Fig. 1).
Because of the diversity of the spatial expression of the endothelin
receptors and the biological effects of ligand binding, consideration of
the various subtle and additional ways that a receptor-mediated re-
sponse is induced is warranted. Indeed, it is prudent to think beyond
the classicalmodel of an endothelin isoform binding to one of two inde-
pendent G protein-coupled receptors to stimulate a well-characterized
response. The differential binding afﬁnity of the ETA receptor for ET-1
and ET-2 over EDN3 has been established (Davenport and Kuc, 2002),
and the ETB receptor appears to bind each ligand with similar afﬁnity;
however, homo- and hetero-dimerization of these receptors (Boesen,
2008), alternate splice variants (Hatae et al., 2007; Shyamala et al.,
1994) and post-translational modiﬁcations (Horstmeyer et al., 1996)
have been reported. Changes in the rate of receptor internalization
(Evans and Walker, 2008; Gregan et al., 2004) and calcium signaling
(Evans and Walker, 2008) are only two of the consequences that
could potentially affect the biological response of receptor binding;
therefore, these changes should also be considered from a functional
viewpoint. Clearly, the ﬁeld of endothelin research has the potential to
yield fruitful results in the coming years.Conﬂict of interest statement
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Fig. 1. Hypothetical interactions between endothelins and receptors in regulating ovulation and luteal formation/luteolysis. ET-1 is constitutively expressed at a low level through-
out the entire ovulatory cycle. ET-2 is abundantly and transiently expressed during the period of ovulation to luteal phases. In spite of the dissimilar expression patterns, the struc-
tural similarity and the extensive experimental evidence indicate that ET-1 and ET-2 likely elicit the same physiological responses following binding to either form of the ET
receptors in the ovary. Therefore, it may be the total ET content that determines the physiological outcomes of ET-mediated regulation of ovarian events. Unlike their ligands,
the two functionally dissimilar ET receptors, ETA and ETB, are constitutively expressed in the ovary. Ovulation and luteal formation, two independent but simultaneous events,
and luteolysis are likely stimulated by ETA receptor activation that may require high concentrations of ETs. The activation of the ETA receptor induces follicular constriction leading
to ovulation, increases VEGF secretion (therefore angiogenesis) promoting luteal formation and stimulates PGE2 and P4 (progesterone) synthesis causing luteolysis. The ovulatory
surge in ET-2 and the luteolytic increase in ET-1 are induced by LH-induced hypoxia and uterus-derived PGF2α, respectively. Meanwhile, the ETB receptor may actively or passively
antagonize these events via an unknown pathway or by reducing ovarian ET content, causing the termination of ETA receptor-initiated events.
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